Your spelling is as good as your analysis. I think it's pretty clear that MNTA's generic copaxone will be approved this year. That will be one less unknown. And I'm getting the sense that Novartis is in the mood for an at-risk launch. Payback for TEVA's generic Lotrel at-risk launch.